J&J Taps Biological E For Up To 500m Coronavirus Vaccine Doses A Year
Indian Firm Also Links With Baylor College
Johnson & Johnson has added a manufacturing base in India’s Biological E as part of a global supply chain for its COVID-19 vaccine candidate. While Biological E will make 400-500 million dosages for the US firm, it has licensed for development another SARS-CoV-2 vaccine candidate from US-based Baylor College of Medicine.
